Comparison of the Efficacy and Safety of Ivermectin to Permethrin
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00262418 |
Recruitment Status :
Completed
First Posted : December 6, 2005
Last Update Posted : December 28, 2007
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Scabies | Drug: Administration of ivermectin or permethrin | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 160 participants |
Allocation: | Randomized |
Intervention Model: | Single Group Assignment |
Masking: | Double |
Primary Purpose: | Treatment |
Official Title: | A Randomised, Double Blind, Double Dummy Study to Compare the Efficacy and Safety of a Single Administration of Ivermectin to a Single Administration of Permethrin for the Treatment of Scabies |
Study Start Date : | July 2004 |
Actual Study Completion Date : | May 2005 |
- Clinical healing of the skin injuries [ Time Frame: on day28 ]
- Decrease of itching [ Time Frame: on day28 ]
- Amelioration of the life quality [ Time Frame: on day28 ]
- Number and gravity of adverse events

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 5 Years and older (Child, Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
At least one of the following inclusion criteria:
- Scabies tunnels
- Positive microscopic examination (acarids, faeces or ova)
At least two of the three following inclusion criteria:
- Non-specific injuries with a typical distribution pattern
- Serious itching which increases during the night
- Family or contacts with similar complaints
Exclusion Criteria:
- Treatment for scabies < 4 weeks ago
- Treatment with corticoids < 1 week ago
- Pregnancy
- Breast-feeding
- HIV
- Serious immunodepressive patients
- Sensitivity or allergy to one of the components of the study medication
- Damage of the central nerve system

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00262418
Belgium | |
University Hospital Ghent | |
Ghent, Belgium, 9000 |
Principal Investigator: | Jean-Marie Naeyaert, MD, PhD | University Hospital, Ghent |
ClinicalTrials.gov Identifier: | NCT00262418 |
Other Study ID Numbers: |
2004/212 |
First Posted: | December 6, 2005 Key Record Dates |
Last Update Posted: | December 28, 2007 |
Last Verified: | December 2007 |
Scabies Mite Infestations Ectoparasitic Infestations Skin Diseases, Parasitic Parasitic Diseases Skin Diseases, Infectious Skin Diseases |
Ivermectin Permethrin Antiparasitic Agents Anti-Infective Agents Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |